U.S. court bars Martin Shkreli from pharma industry, orders $64.6 million payment -Breaking
[ad_1]
© Reuters. FILE PHOTO – Martin Shkreli (ex-executive of a drug firm) leaves U.S. District Court, after being convicted in New York City of Securities Fraud. The incident took place in Brooklyn, NY, U.S.A, on August 4, 2017. REUTERS/Carlo AllegriWASHINGTON (Reuters), A U.S. Court ruled that Martin Shkreli, the famously high-priced Daraprim, would have to fork over $64.6million and be permanently barred from the drug industry.
This drug can be used to treat Toxoplasmosis. It is a parasitic infection that poses a threat to people who have weak immune systems.
Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]